XTENT, Inc.

As of May 18, 2009, XTENT, Inc. went out of business. XTENT, Inc. develops customizable Drug-Eluting Stent (DES) systems for the treatment of coronary artery disease. It offers Custom NX 36, which is used to treat single or multiple lesions; and Custom NX 60 that is designed to give physicians a suitable length stent to treat one long lesion or multiple smaller lesions. The company’s NX DES systems are in custom care clinical trials. Its drug eluting stent systems are designed to enable physicians to customize length and diameter of the stent at the site of the diseased section of the artery or lesion. The company develops 36 and 60 millimeter stent systems based on its proprietary technology platform. XTENT, Inc. was founded in 2001 and is based in Menlo Park, California.